Ncardia’s iPSC-derived microglia may aid ALS research and help to screen new therapies that target inflammation in ALS.

ALS is a disease of continual losses and trade-offs. We walk a tightrope between safety and independence, and caution and quality of life.

Columnist Dagmar Munn turns to affirmations and positive self-talk on those occasional days when she feels shut down.

The genes included those involved in the function of energy-producing mitochondria, lipid and iron metabolism, and the ...

New York was the only state to receive the highest mark on the ALS Association’s latest report cards, the association said.

A 22-month survival benefit was seen for a subset of ALS patients whose disease did not progress when treated with NP001 in ...

ALS took many things from columnist Juliet Taylor's late husband, Jeff, including the end of his career, which was ...

Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.

Riluzole treatment and a diet containing high glycemic index foods interact 'synergistically' to slow ALS progression, ...

With the hold lifted, Amylyx can begin screening and enrolling for its Phase 1 LUMINA trial, which will test AMX0114 in ALS ...

The ALS Association will host its second ALS Nexus conference in August, with the goal of making the disease a livable one ...